Global Furazolidone Market Insights, Forecast to 2028

SKU ID :QYR-20154929 | Published Date: 08-Feb-2022 | No. of pages: 111
Furazolidone is a nitrofuran derivative with antiprotozoal and antibacterial activity. Furazolidone binds bacterial DNA which leads to the gradual inhibition of monoamine oxidase
Market Analysis and Insights: Global Furazolidone Market
Due to the COVID-19 pandemic, the global Furazolidone market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, Pharma Grade accounting for % of the Furazolidone global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Pharmacy segment is altered to an % CAGR throughout this forecast period.
China Furazolidone market size is valued at US$ million in 2021, while the US and Europe Furazolidone are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Furazolidone landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Furazolidone include Becton, Dickinson and Company (BD), Daiichi Sankyo, GrÜNenthal Gmbh, Standpharm, Teva, Marvi, Ferring, Geo-Med and KPL Pharma and etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Furazolidone Scope and Segment
Furazolidone market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Furazolidone market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Pharma Grade
Industrial Grade
Others
Segment by Application
Pharmacy
Industry
By Company
Becton, Dickinson and Company (BD)
Daiichi Sankyo
GrÜNenthal Gmbh
Standpharm
Teva
Marvi
Ferring
Geo-Med
KPL Pharma
Keyfarm
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
  • PRICE
  • $4900
    $9800
    $7350
    Buy Now

Our Clients